Naftidrofuryl

Naftidrofuryl

Clinical data
Trade names	Praxilene
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C04AX21 ( WHO )
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	1 - 3.5 hours
Identifiers
IUPAC name (RS)-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate
CAS Number	31329-57-4  Y
PubChem CID	4417
ChemSpider	4264  Y
UNII	42H8PQ0NMJ
ChEMBL	ChEMBL1620794
CompTox Dashboard (EPA)	DTXSID3023344
ECHA InfoCard	100.045.960
Chemical and physical data
Formula	C24H33NO3
Molar mass	383.532 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCCN(CC)CC)C(Cc2c1ccccc1ccc2)CC3OCCC3
InChI InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3 Y Key:KBAFPSLPKGSANY-UHFFFAOYSA-N Y
(verify)

Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT₂ receptors (with action as an inverse agonist of the 5-HT_2A receptor specifically characterized). ^{[1] [2] [3]} Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.

Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.

Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus. ^[4]

Naftidrofuryl may be effective for relieving the pain of muscle cramps. ^[5]

Adverse Effects

Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported. ^[6]

See also

• Ketanserin
• Sarpogrelate

References

1. Lanzer P, Topol EJ (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN   978-3-642-56225-9.
2. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN   978-94-011-4439-1.
3. Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T (August 2009). "Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–50. doi: 10.1254/jphs.09124FP . PMID   19672037.
4. "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de. Archived from the original on 2018-09-20. Retrieved 2018-12-13.
5. Katzberg HD, Khan AH, So YT (February 2010). "Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology". Neurology. 74 (8): 691–6. doi: 10.1212/WNL.0b013e3181d0ccca . PMID   20177124.
6. Brayfield A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.